Initiating insulin in patients with type 2 diabetes

CMAJ. Canadian Medical Association Journal

Volumn 184, Issue 7, 2012, Pages 767-776

  Lau, Adrian N C ^a   Tang, Terence ^a   Halapy, Henry ^b   Thorpe, Kevin ^c   Yu, Catherine H Y ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDEPRESSANT AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO;

BEDTIME DOSAGE; BLOOD GLUCOSE MONITORING; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES EDUCATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; EDEMA; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; INJECTION SITE PAIN; INSULIN RELEASE; INSULIN TREATMENT; LIPODYSTROPHY; MORNING DOSAGE; NEPHROTIC SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PATIENT EDUCATION; PERIPHERAL EDEMA; QUALITY OF LIFE; REVIEW; SELF MONITORING; SIDE EFFECT; WEIGHT GAIN;

EID: 84859815892     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.110779     Document Type: Review

References (99)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87:4-14.
2. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91. (Pubitemid 351214285)
3. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-9. (Pubitemid 43951158)
4. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32(Suppl 1):S1-201.
5. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203.
6. Clinical Guidelines Task Force. Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-93.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
8. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
9. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-60. (Pubitemid 351697950)
10. Gerstein H, Yusuf S, Riddle MC, et al.; Origin Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32.
11. Seaquist ER, Ibrahim HN. Approach to the patient with type 2 diabetes and progressive kidney disease. J Clin Endocrinol Metab 2010;95:3103-10.
12. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, et al. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009;15:280-8.
13. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-32. (Pubitemid 44870902)
14. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74. (Pubitemid 44125921)
15. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-12. (Pubitemid 36929141)
16. Paterson KR, Wilson M, Kesson CM, et al. Comparison of basal and prandial insulin therapy in patients with secondary failure of sulphonylurea therapy. Diabet Med 1991;8:40-3.
17. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736-47.
18. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006;32:910-7. (Pubitemid 44706818)
19. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
20. Olsson PO, Lindstrom T. Combination-therapy with bedtime NPH insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes. Diabetes Metab 2002;28:272-7.
21. Birkeland KI, Rishaug U, Hanssen KF, et al. NIDDM: a rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 1996;39:1629-33.
22. Cohen O, Norymberg C, Neumann E, et al. Weight gain in type 2 diabetes mellitus - Not all uphill. Diabetes Res Clin Pract 2008; 79: 128-32.
23. Birkeland KI, Hanssen KF, Urdal P, et al. A long-term, randomized, comparative study of insulin versus sulfonylurea therapy in type 2 diabetes. J Intern Med 1994;236:305-13. (Pubitemid 24283070)
24. Yki-Järvinen H, Ryysy L, Kauppila M, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997;82:4037-43. (Pubitemid 27525508)
25. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in type 2 diabetes: family physicians' misconception of patients'fears contributes to existing barriers. J Diabetes Complications 2007; 21:220-6. (Pubitemid 47002315)
26. Groop L, Widen E, Franssila-Kallunki A, et al. Different effects of insulin and oral antidiabetic agents on glucose and energy metabolism in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:599-605. (Pubitemid 19215442)
27. Yki-Järvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
28. Hendra TJ, Taylor CD. A randomised trial of insulin on well-being and carer strain in elderly type 2 diabetic subjects. J Diabetes Complications 2004;18:148-54. (Pubitemid 38622542)
29. Rodier M, Colette C, Gouzes C, et al. Effects of insulin therapy upon plasma lipid fatty acids and platelet aggregation in NIDDM with secondary failure to oral antidiabetic agents. Diabetes Res Clin Pract 1995;28:19-28.
30. Harris S, Yale JF, Dempsey E, et al. Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Can Fam Physician 2008;54:550-8. (Pubitemid 351554055)
31. Ushakova O, Sokolovskaya V, Morozova A, et al. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in Russia. Clin Ther 2007;29:2374-84.
32. Papa G, Fedele V, Chiavetta A, et al. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008;45:53-9.
33. Ko GT, Tsang PC, Wai HP, et al. Rosiglitazone versus bedtime insulin in the treatment of patients with conventional oral antidiabetic drug failure: a 1-year randomized clinical trial. Adv Ther 2006; 23:799-808. (Pubitemid 44955861)
34. Schwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003;26:2238-43. (Pubitemid 36993306)
35. Alvarsson M, Sundkvist G, Lager I, et al. Effects of insulin v. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. Diabetes Obes Metab 2008;10:421-9. (Pubitemid 351524289)
36. Raz I, Stranks S, Filipczak R, et al. Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. Clin Ther 2005;27:1432-43. (Pubitemid 41598374)
37. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004;27:2585-9. (Pubitemid 39441455)
38. Klein W. Sulfonylurea-metformin-combination versus sulfonyl - urea-insulin-combination in secondary failures of sulfonylurea monotherapy. Results of a prospective randomized study in 50 patients. Diabete Metab 1991;17:235-40.
39. Pibernik-Okanovic M, Szabo S, Metelko Z. Quality of life following a change in therapy for diabetes mellitus. Pharmacoeconomics 1998;14:201-7. (Pubitemid 28370832)
40. Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract 2007;78:254-8. (Pubitemid 47451531)
41. Taylor R, Foster B, Kyne-Grzebalski D, et al. Insulin regimens for the non-insulin dependent: impact on diurnal metabolic state and quality of life. Diabet Med 1994;11:551-7. (Pubitemid 24227354)
42. Brunton S. Insulin delivery systems: reducing barriers to insulin therapy and advancing diabetes mellitus treatment. Am J Med 2008; 121(Suppl):S35-41. (Pubitemid 351726337)
43. Brown JB, Harris SB, Webster-Bogaert S, et al. The role of patient, physician and systemic factors in the management of type 2 diabetes mellitus. Fam Pract 2002;19:344-9. (Pubitemid 34846832)
44. Peyrot M, Rubin RR, Khunti K. Addressing barriers to initiation of insulin in patients with type 2 diabetes. Prim Care Diabetes 2010; 4(Suppl 1):S11-8.
45. Brown SA. Meta-analysis of diabetes patient education research: variations in intervention effects across studies. Res Nurs Health 1992; 15:409-19.
46. Brown SA. Effects of educational interventions in diabetes care: a meta-analysis of findings. Nurs Res 1988;37:223-30.
47. Shah BR, Hux JE, Laupacis A, et al. van WC. Diabetic patients with prior specialist care have better glycaemic control than those with prior primary care. J Eval Clin Pract 2005;11:568-75. (Pubitemid 41794024)
48. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006;296:427-40. (Pubitemid 44127527)
49. Weber C. Challenges in funding diabetes care: a health economic perspective. Expert Rev Pharmacoecon Outcomes Res 2010; 10:517-24.
50. Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture v. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52. (Pubitemid 44316603)
51. Janka HU, Plewe G, Riddle MC, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28:254-9. (Pubitemid 40170922)
52. Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5. (Pubitemid 40170923)
53. Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-13.
54. Wolffenbuttel BH, Klaff LJ, Bhushan R, et al. Initiating insulin therapy in elderly patients with type 2 diabetes: efficacy and safety of lispro mix 25 v. basal insulin combined with oral glucose-lowering agents. Diabet Med 2009;26:1147-55.
55. Goudswaard AN, Stolk RP, Zuithoff P, et al. Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract 2004;53:393-9. (Pubitemid 38621157)
56. Milicevic Z, Hancu N, Car N, et al. Effect of two starting insulin regimens in patients with type 2 diabetes not controlled on a combination of oral antihyperglycemic medications. Exp Clin Endocrinol Diabetes 2009;117:223-9.
57. Stehouwer MH, DeVries JH, Lumeij JA, et al. Combined bedtime insulin-daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate - a randomised trial. Diabetes Metab Res Rev 2003;19:148-52. (Pubitemid 36417199)
58. Davies M, Evans R, Storms F, et al. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. Diabetes Obes Metab 2007;9:706-13. (Pubitemid 47261852)
59. Strojek K, Bebakar WM, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009; 25:2887-94.
60. Kilo C, Mezitis N, Jain R, et al. Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin. J Diabetes Complications 2003;17:307-13. (Pubitemid 37315939)
61. Landstedt-Hallin L, Adamson U, Arner P, et al. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995; 18:1183-6.
62. Bastyr EJ III, Johnson ME, Trautmann ME, et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. Clin Ther 1999;21:1703-14. (Pubitemid 29523365)
63. Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073-84. (Pubitemid 351436611)
64. Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose tolerance in type 2 diabetic patients: traditional v. modern insulin regimens (results from the Austrian Biaspart Study). Horm Metab Res 2005;37:684-9. (Pubitemid 41810491)
65. Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149:531-9.
66. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81. (Pubitemid 44856694)
67. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6. (Pubitemid 30616801)
68. Taylor R, Davies R, Fox C, et al. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000;23:1612-8.
69. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6. (Pubitemid 37339502)
70. Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96. (Pubitemid 36577862)
71. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; (2): CD005613.
72. Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8.
73. Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8.
74. Wolffenbuttel BH, Sels JP, Rondas-Colbers GJ, et al. Comparison of different insulin regimens in elderly patients with NIDDM. Diabetes Care 1996;19:1326-32. (Pubitemid 26418609)
75. Zargar AH, Masoodi SR, Laway BA, et al. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. J Assoc Physicians India 2002;50:641-6.
76. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:271-86.
77. Altuntas Y, Ozen B, Ozturk B, et al. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure. Diabetes Obes Metab 2003;5:371-8. (Pubitemid 37483598)
78. Davies MJ, Thaware PK, Tringham JR, et al. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabet Med 2007;24:714-9. (Pubitemid 47018139)
79. Gerstein HC, Yale JF, Harris SB, et al. A randomized trial of adding insulin glargine v. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or sub-maximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23:736-42. (Pubitemid 44366071)
80. Oyer DS, Shepherd MD, Coulter FC, et al. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial). Am J Med 2009;122:1043-9.
81. Selam JL, Koenen C, Weng W, et al. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11-20. (Pubitemid 351160234)
82. Yki-Järvinen H, Juurinen L, Alvarsson M, et al. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007;30:1364-9. (Pubitemid 46871139)
83. Davies M, Storms F, Shutler S, et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282-8. (Pubitemid 40756686)
84. Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008;31:1305-10.
85. Sun Y, Xiong Y, Yang J. The effectiveness of combined insulin and sulfonylurea in treating non-insulin dependent diabetic patients. Zhonghua Nei Ke Za Zhi 1995;34:246-9.
86. Wolffenbuttel BH, Rondas-Colbers GJ, Menheere PP, et al. The effects of insulin combined with glibenclamide on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Ned Tijdschr Geneeskd 1991;135:1080-4.
87. Douek IF, Allen SE, Ewings P, et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomized placebo-controlled trial. Diabet Med 2005; 22: 634-40. (Pubitemid 40593142)
88. Civera M, Merchante A, Salvador M, et al. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. Diabetes Res Clin Pract 2008;79:42-7.
89. Yki-Järvinen H, Ryysy L, Nikkila K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999;130:389-96. (Pubitemid 29111220)
90. Fövényi J, Grosz A, Thaisz E, et al. [Daytime sulfonyluyrea -bedtime insulin combination therapy in type 2 diabetes.] Magy Belorv Arch (Hungarian Archive of Internal Medicine) 1997; 50: 607-13.
91. Riddle M, Hart J, Bingham P, et al. Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfo - nylurea. Am J Med Sci 1992;303:151-6.
92. Shank ML, Del PS, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995;44:165-72.
93. Xu WC, Chen CR, Chen YS. Combination therapy with bedtime insulin and daytime oral hypoglycaemic agests in type 2 diabetic patients. Hebei Med J 2001:23-4.
94. Kabadi MU, Kabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann Pharmacother 2003;37:1572-6. (Pubitemid 37315093)
95. Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group. Diabetes Care 1998; 21: 1052-7. (Pubitemid 28368507)
96. Chow CC, Tsang LW, Sorensen JP, et al. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients. Diabetes Care 1995;18:307-14.
97. Lotz N, Bachmann W, Ladik T, et al. Combination therapy with insulin/sulfonylurea in the long-term therapy of type 2 diabetes following "secondary failure." Klin Wochenschr 1988;66:1079-84. (Pubitemid 18261101)
98. Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS ONE 2009;4:e6112.
99. Schnell O, Mertes G, Standl E. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy. Diabetes Obes Metab 2007;9:853-8. (Pubitemid 47555206)